Trial Profile
A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2017
Price :
$35
*
At a glance
- Drugs Fenebrutinib (Primary)
- Indications Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus; Urticaria
- Focus Adverse reactions
- Sponsors Roche
- 14 Aug 2017 Status changed from recruiting to completed.
- 20 Jun 2017 New trial record